Zhong Ji LS Announces 30 June 2026 AGM; Seeks Approval for FY-2025 Results, Board Re-election and 20% Issuance Mandate

Bulletin Express
06/08

Zhong Ji Longevity Science Group Limited (abbreviated: Zhong Ji LS) has issued its proxy form and agenda for the Annual General Meeting (AGM) scheduled for 30 June 2026 at 10:30 a.m. at 30/F, Harbour Side HQ, 8 Lam Chak Street, Kowloon Bay, Hong Kong.

Key matters to be tabled as ordinary resolutions include:

1. Financial Statements • Shareholders will vote on receiving and considering the audited consolidated financial statements for the year ended 31 December 2025, together with the directors’ and auditor’s reports.

2. Board Composition and Remuneration • Re-election of four directors: – Mr. Yan Li (Executive Director) – Mr. Lyu Changsheng (Non-executive Director) – Ms. Wang Huijuan (Independent Non-executive Director) – Ms. Tam Mei Chu (Independent Non-executive Director) • Authorisation for the board to determine directors’ remuneration for the ensuing year.

3. Auditor Appointment • Proposal to re-appoint CCTH CPA Limited as the Company’s auditor until the next AGM and to empower the board to fix its remuneration.

4. Share Capital Mandates • General mandate permitting the board to issue and deal with additional shares representing up to 20% of the total shares in issue as at the date of the resolution. • Authority to repurchase shares on-market up to 10% of the issued share capital. • Extension of the 20% issuance mandate by adding the number of shares repurchased under the 10% buy-back authority.

Shareholders who wish to vote via proxy must submit duly completed proxy forms to the Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, no later than 48 hours before the meeting. Attendance in person remains an option, with any lodged proxy rendered void upon personal attendance.

These resolutions collectively address corporate governance, capital management flexibility, and auditor continuity as Zhong Ji LS prepares to review its FY-2025 performance and strategic mandates for the coming year.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10